Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jul 24, 2024; 15(7): 895-907
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.895
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.895
Parthenolide enhances the metronomic chemotherapy effect of cyclophosphamide in lung cancer by inhibiting the NF-kB signaling pathway
Zheng Cai, Qi-Ming Wang, Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China
Zheng Cai, Lang Gao, Kai Hu, Department of Oncology, The No. 1 Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming 650021, Yunnan Province, China
Author contributions: Cai Z and Wang QM conceived and designed the experiments; Cai Z, Gao L, Hu K, and Wang QM performed the experiments; Cai Z and Gao L analyzed and interpreted the data; Hu K, and Wang QM contributed reagents/materials/analysis tools; Cai Z wrote original draft; Gao L, Hu K, and Wang QM reviewed and edited draft; All authors have read and agreed to the published version of the manuscript.
Supported by Joint Funding of Yunnan Ministry of Science and Technology , No. 2019FF002-048 ; and Beijing Heathco Clinical Oncology Research Foundation , No. Y-Q201802-048 .
Institutional animal care and use committee statement: All animal experimental procedures were approved by the ethics committee of the Affiliated Hospital of Yunnan University of Traditional Chinese Medicine (Approval No. DW2022-016) and performed according to the institutional animal care guidelines.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request at qimingwang1006@126.com.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qi-Ming Wang, PhD, Doctor, Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, No. 127 Dong Ming Road, Zhengzhou 450008, Henan Province, China. qimingwang1006@126.com
Received: February 26, 2024
Revised: May 11, 2024
Accepted: June 6, 2024
Published online: July 24, 2024
Processing time: 140 Days and 19.6 Hours
Revised: May 11, 2024
Accepted: June 6, 2024
Published online: July 24, 2024
Processing time: 140 Days and 19.6 Hours
Core Tip
Core Tip: Our present study found that as a specific inhibitor of NF-kB, Parthenolide can promote the efficiency of cyclophosphamide in lung cancer via inhibiting NF-kB signaling in vitro and in vivo. Our present study will help scientists and clinicians to draw up novel rhythmic chemotherapy strategies.